Categories: News

Edison Issues Report on Verve Group (VRV)

London, United Kingdom–(Newsfile Corp. – June 25, 2025) – Edison issues report on Verve Group (FRA: VRV).

The Verve Group has successfully completed a directed share issue of 12.9m new shares, raising SEK360m (€32.5m), with which it intends to scale its sales capacity, develop new product solutions, invest further in AI and expand into emerging areas such as retail media (with maximum leverage of 2.5x). This comes on the heels of a bond refinancing, reducing interest costs. Q1 figures showed revenues up 32% on Q124, delivering an adjusted EBITDA margin of 28%. We have edged revenue expectations up, but take a more cautious view on margins given the accelerated investment programme. Verve’s privacy-first and AI-driven solutions position it well to gain further market share. In our view, the valuation remains undemanding.

Click here to read the full report.

All reports published by Edison are available to download free of charge from its website
www.edisongroup.com

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

enquiries@edisongroup.com

Connect with Edison on:

LinkedIn www.linkedin.com/company/edison-group-/
X www.x.com/edison_inv_res
YouTube www.youtube.com/edisonitv

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/256773

Staff

Recent Posts

Vaxxas Secures TGA Licence to Manufacture Therapeutic Goods

Milestone enables GMP manufacturing to accelerate clinical trials and transform global vaccine delivery BRISBANE, Australia…

14 hours ago

InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial

BEIJING, Dec. 14, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading…

14 hours ago

President Trump’s Cannabis Decision Is Coming – And Why MMJ International Holdings Wins Either Way

12 Month Timeline - How Cannabis Rescheduling Actually Takes EffectAnnouncementPresident signals intent or issues executive…

1 day ago

Accelerating Patient Recruitment and Research Excellence: TrialWire® Supports Endpoints Clinical Trials Day NYC 2025

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- TrialWire®, the industry’s fastest, intelligent patient recruitment…

2 days ago

Genesis Healthcare Remains Committed to Securing Longterm Stability

The skilled nursing, assisted and senior living provider reiterates dedication to a financial restructuring process…

2 days ago